DepY​med

About

DepYmed Inc., is a New York based cancer therapeutic development company. DepYmed’s lead compound in development is MSI-1436C (Trodusquemine), a potent inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). MSI-1436C is currently in clinical development as a therapeutic candidate for HER2-positive breast cancer. A Phase 1 clinical study evaluating the safety of MSI-1436C in breast cancer patients was initiated in November 2015 at the Monter Cancer Center – a state of the art cancer treatment center and part of Northwell Health. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors as therapeutic agents.